Synthesis of Benzodiazepine CGRP Antagonist via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one, a key component in CGRP antagonists for oral migraine therapy, face challenges in achieving high yields and purity.
Innovation Solution
A multi-step process involving the reaction of 2-nitrophenylacetic acid with 4-amino-N-phenylmethylpiperidine using specific condensing agents, followed by hydrogenation, carbamoylation, reduction, and finally removal of the benzyl protecting group, utilizing various solvents and catalysts to achieve the desired compound in high yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current methods are used to prepare 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one, then the compound can be obtained, but the yields are low and chemical purity is insufficient
Solution Approach 1:
The synthesis process is divided into multiple discrete steps: (1) condensation of 2-nitrophenylacetic acid with 4-amino-N-phenylmethylpiperidine to form the amide intermediate, (2) catalytic hydrogenation to reduce the nitro group, (3) carbamoylation to introduce the carbamate group, and (4) cyclization to form the final benzodiazepine structure. Each step is optimized independently to maximize both yield and purity, resolving the contradiction between productivity and manufacturing precision.
Solution Approach 2:
The method employs preliminary protection of the amino group as a carbamate (using esters such as di-tert-butyl pyrocarbonate or chloroformic acid esters) before the cyclization step. This preliminary action prevents unwanted side reactions during the synthesis and ensures high chemical purity of the final product while maintaining good overall yield through efficient protective group strategy.
2Manufacturing precision
If multiple synthesis steps are employed to achieve high purity, then manufacturing precision improves, but the process complexity increases
Solution Approach 1:
The patent uses specific intermediates with well-defined structures and properties: the amide intermediate from condensation, the reduced amine after hydrogenation, and the carbamoylated intermediate before cyclization. Each intermediate serves as a mediator that directs the reaction toward the desired product with high purity. The use of standardized intermediates simplifies process control and reduces overall complexity despite multiple steps.
Solution Approach 2:
The synthesis employs systematic parameter optimization: condensation at controlled temperatures with specific condensing agents (carbonyldiimidazole, dicyclohexylcarbodiimide, TBTU), hydrogenation at 20-60°C with 2.5-20% metal catalysts under excess hydrogen pressure, and carbamoylation with controlled equivalents of base and ester. These parameter changes enable high purity production while maintaining reasonable process complexity through standardized conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process effectively produces the compound in good yields and high chemical purity, making it suitable for pharmaceutical applications as a CGRP antagonist.
Implementation Method 1
the nitro group hydrogenated by the addition of a metal catalyst, preferably 2.5 to 20%, particularly preferably 4 to 6%, to form a compound of formula III
Implementation Method 2
the crude product of formula II is carbamoylated in solution by the addition of at least one equivalent, preferably 1.0 to 2.0 equivalents, particularly preferably 1.6 equivalents, an ester and in the presence of at least one equivalent, preferably 1.0 to 2.0 equivalents, particularly preferably 1.6 equivalents, of a base
Implementation Method 3
the carbonyl group is converted into a methylene group by the addition of at least 2 equivalents, preferably 4.0 to 8.0 equivalents, of a reducing agent
Data Source
AI summary
The present invention relates to a process for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one of formula which is to be found as a structural element in CGRP antagonists which are suitable above all for the oral therapy of migraine.